TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07625644: BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

Sponsor: SystImmune Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 550 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT07625644 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07625644 Rescue Dossier →